{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["23(1)"],"submitter":["Skarbaliene J"],"funding":["Zealand Pharma A/S"],"pubmed_abstract":["<h4>Background</h4>Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for treatment of short bowel syndrome. Here, we investigated if glepaglutide is therapeutically beneficial in rats with small intestinal inflammation.<h4>Methods</h4>Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages. Glepaglutide was administered in co-treatment and post-treatment regimens. Small intestinal length and concentrations of inflammatory markers α-1-acid glycoprotein and myeloperoxidas"],"journal":["BMC gastroenterology"],"pagination":["79"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10029296"],"repository":["biostudies-literature"],"pubmed_title":["Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats."],"pmcid":["PMC10029296"],"pubmed_authors":["Mathiesen JM","Thorkildsen C","Larsen BD","Petersen YM","Skarbaliene J"],"additional_accession":[]},"is_claimable":false,"name":"Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.","description":"<h4>Background</h4>Glucagon-like peptide-2 (GLP-2) enhances intestinal repair and attenuates inflammation in preclinical inflammatory bowel disease (IBD) models, making GLP-2 analogues attractive candidates for IBD therapy. Glepaglutide is a long-acting GLP-2 receptor agonist in clinical development for treatment of short bowel syndrome. Here, we investigated if glepaglutide is therapeutically beneficial in rats with small intestinal inflammation.<h4>Methods</h4>Small intestinal inflammation was induced with indomethacin in naive Wistar rats, followed by glepaglutide administration at different disease stages. Glepaglutide was administered in co-treatment and post-treatment regimens. Small intestinal length and concentrations of inflammatory markers α-1-acid glycoprotein and myeloperoxidas","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-28T10:58:00.158Z","creation":"2024-11-05T18:06:00.387Z"},"accession":"S-EPMC10029296","cross_references":{"pubmed":["36944922"],"doi":["10.1186/s12876-023-02716-4"]}}